The Leronlimab approvals for combo open the door to paradise for CYDY, as this is not just one indication, the ability to use Leronlimab off-label for dozens of cancers with metastases where CCR5 is expressed, as it has been proven effective and safe.
I've been saying this for a long time, when Leronlimab is approved for a combo, Leronlimab will be approved on the market, and no one can ban its use for other indications, the FDA only not allows advertising off-label. We will have an approved drug on the market which has a proven track record of many indications where patients are at risk of life. Leronlimab will also be used as mono because studies prove it, but I expect its widespread use in many cancers with metastasis where CCR5 is expressed. And the need is enormous because many drugs quickly develop resistance and the patient needs something else.